Allakos (ALLK) Cut to “Sell” at Zacks Investment Research

Zacks Investment Research lowered shares of Allakos (NASDAQ:ALLK) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.

According to Zacks, “Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based in CA, United States. “

ALLK has been the subject of several other reports. Jefferies Financial Group assumed coverage on Allakos in a research note on Monday, August 13th. They issued a buy rating and a $53.00 target price for the company. William Blair assumed coverage on Allakos in a research note on Monday, August 13th. They issued an outperform rating for the company. Finally, Goldman Sachs Group assumed coverage on Allakos in a research note on Monday, August 13th. They issued a neutral rating and a $31.00 target price for the company.

NASDAQ ALLK opened at $58.91 on Tuesday. Allakos has a 52 week low of $26.00 and a 52 week high of $62.00.

Allakos (NASDAQ:ALLK) last released its earnings results on Thursday, November 8th. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.10). Sell-side analysts predict that Allakos will post -1.23 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the company. Strs Ohio bought a new position in shares of Allakos in the 3rd quarter worth $107,000. American International Group Inc. bought a new position in shares of Allakos in the 3rd quarter worth $247,000. Rhumbline Advisers bought a new position in shares of Allakos in the 3rd quarter worth $285,000. Blair William & Co. IL bought a new position in shares of Allakos in the 3rd quarter worth $346,000. Finally, MetLife Investment Advisors LLC bought a new position in shares of Allakos in the 3rd quarter worth $434,000. Institutional investors and hedge funds own 16.92% of the company’s stock.

Allakos Company Profile

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Further Reading: Moving Average (MA)

Get a free copy of the Zacks research report on Allakos (ALLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit